Abramczyk R et al (2020) Diabetes and psoriasis: different sides of the same prism. Diabetes Metab Syndr Obes 13:3571–3577

Article  CAS  PubMed  PubMed Central  Google Scholar 

Armstrong AW et al (2021) Psoriasis prevalence in adults in the United States. JAMA Dermatol 157(8):940–946

Article  PubMed  Google Scholar 

Haran K et al (2024) Impact of GLP-1 receptor agonists on psoriasis and cardiovascular comorbidities: a narrative review. Psoriasis (Auckl) 14:143–152

PubMed  Google Scholar 

Takeshita J et al (2017) Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol 76(3):377–390

Article  PubMed  PubMed Central  Google Scholar 

Wu JJ et al (2022) Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol 36(6):797–806

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karacabeyli D et al (2024) Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: a population-based study. PLoS One 19(8)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shaefer CF Jr., Kushner P, Aguilar R (2015) User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med 127(8):818–826

Article  PubMed  Google Scholar 

Cerillo JL, Parmar M (2025) Liraglutide. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island

Brandfon S et al (2023) Advances in anti-obesity pharmacotherapy: current treatments, emerging therapies, and challenges. Cureus 15(10)

PubMed  PubMed Central  Google Scholar 

Miranda S et al (2025) Impact of semaglutide on lipid profiles in overweight and obese non-diabetic adults: a systematic review and meta-analysis of randomized controlled trials. Eur J Pharmacol 1003

Article  CAS  PubMed  Google Scholar 

Burshtein J et al (2025) The association between obesity and efficacy of psoriasis therapies: an expert consensus panel. J Am Acad Dermatol 92(4):807–815

Article  CAS  PubMed  Google Scholar 

Faurschou A et al (2014) Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. Acta Diabetol 51(1):147–150

Article  CAS  PubMed  Google Scholar 

Ramakrishnan S et al (2020) Remarkable improvement in plaque psoriasis with a 4 week short course liraglutide therapy in an obese type 2 DM patient. J Endocrinol Sci. https://doi.org/10.29245/2767-5157/2020/1.1106

Article  Google Scholar 

Buysschaert M, Tennstedt D, Preumont V (2012) Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes Metab 38(1):86–88

Article  CAS  PubMed  Google Scholar 

Hogan AE et al (2011) Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia 54(11):2745–2754

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malavazos AE, Meregalli C, Sorrentino F, Vignati A, Dubini C, Scravaglieri V, Basilico S, Boniardi F, Spagnolo P, Malagoli P, Romanelli P, Secchi F, Iacobellis G (2023) Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes. Endocrinol Diabetes Metab Case Rep 2023(3):23–0017. https://doi.org/10.1530/EDM-23-0017

Costanzo G et al (2021) Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol Diabetes Metab Case Rep 2021:21-0007

Nowowiejska J, Baran A, Flisiak I (2023) The first case of psoriatic skin lesions exacerbation after liraglutide. Pol Arch Intern Med 133(7–8):165–27

Google Scholar 

Petkovic-Dabic J et al (2025) Effects of semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial. Biomolecules 15(1):46

Lin L et al (2022) Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. J Dermatolog Treat 33(3):1428–1434

Article  CAS  PubMed  Google Scholar 

Faurschou A et al (2015) Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients–a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol 29(3):555–559

Article  CAS  PubMed  Google Scholar 

Nicolau J et al (2023) Effects of liraglutide among patients living with psoriasis and obesity. Med Clin (Barc) 161(7):293–296

Article  CAS  PubMed  Google Scholar 

Xu X et al (2019) Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study. Diabetes Res Clin Pract 150:167–173

Article  CAS  PubMed  Google Scholar 

Ahern T et al (2013) Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol 27(11):1440–1443

Article  CAS  PubMed  Google Scholar 

Buysschaert M et al (2014) Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal gammadelta T-cell number: a prospective case-series study. Br J Dermatol 171(1):155–161

Article  CAS  PubMed  Google Scholar 

Yang J, Wang Z, Zhang X (2019) GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK. Exp Mol Pathol 107:124–128

Article  CAS  PubMed  Google Scholar 

Faurschou A et al (2013) Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Exp Dermatol 22(2):150–152

Article  CAS  PubMed  Google Scholar 

Jensen P, Skov L (2016) Psoriasis and obesity. Dermatology 232(6):633–639

Article  PubMed  Google Scholar 

Hogan AE et al (2014) Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia 57(4):781–784

Article  CAS  PubMed  Google Scholar 

Mahase E (2024) GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment. BMJ 386:q1645. https://doi.org/10.1136/bmj.q1645

Harris E (2024) Poll: roughly 12% of US adults have used a GLP-1 drug, even if unaffordable. JAMA 332(1):8. https://doi.org/10.1001/jama.2024.10333

Article  PubMed  Google Scholar 

Laurindo LF et al (2022) GLP-1a: going beyond traditional use. Int J Mol Sci. https://doi.org/10.3390/ijms23020739

Article  PubMed  PubMed Central  Google Scholar 

Elmets CA et al (2021) Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol 84(2):432–470

Article  PubMed  Google Scholar 

Menter A et al (2019) Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 80(4):1029–1072

Article  PubMed  Google Scholar